Ignite Creation Date:
2025-12-24 @ 4:21 PM
Ignite Modification Date:
2026-01-10 @ 2:32 PM
Study NCT ID:
NCT06202066
Status:
SUSPENDED
Last Update Posted:
2025-12-19
First Post:
2023-12-29
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas
Sponsor:
Roswell Park Cancer Institute
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
I 3622923
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None